Peptidream Inc. has reported that an early-phase clinical trial for 64Cu-PD-32766, a 64Cu-labeled radiopharmaceutical targeting carbonic anhydrase IX (CAIX), for patients with clear cell renal cell carcinoma has been approved by the clinical review board of the National Cancer Center Hospital East in Japan.
Researchers from Haisco Pharmaceutical Group Co. Ltd. presented the discovery and preclinical characterization of a brain-penetrating BRAF paradox breaker, HSK-42360, being developed for the treatment of BRAF-driven cancers. HSK-42360 proved to be a potent BRAF V600E inhibitor (IC50=5 nM) with selectivity over wild-type BRAF.
Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has developed a new small-molecule oral compound for the treatment of Parkinson’s disease, FHND-1002, which demonstrated neuronal protection in models of neurodegenerative diseases and neuron trauma.
Pain treatment, especially non-addictive treatment for severe pain, remains a critical unmet need. Among the TRP channels, transient receptor potential cation channel subfamily M member 3 (TRMP3) is a channel expressed in somatosensory neurons, including nociceptors of rodents and humans.
Werner syndrome helicase (WRN), which plays important roles in DNA repair and maintenance of genome integrity, has been recently identified as therapeutic target for microsatellite instability (MSI)-H tumors, which have deficiencies in DNA damage repair.
Epidermal growth factor receptor (EGFR) is widely expressed among multiple cancer types, but patients often develop resistance to EGFR tyrosine kinase inhibitors (TKIs), which may be accompanied by increased expression of CD70.
Researchers from Biohaven Pharmaceuticals Inc. presented preclinical data for the first-in-class extracellular bispecific IgG degrader, BHV-1300, being developed for the treatment of neuroinflammatory and autoimmune disease.
Multiple myeloma (MM) is still an uncurable disease. Chimeric antigen receptor (CAR) T cells directed to tumor necrosis factor receptor superfamily member 17, also known as BCMA, have transformed the field, with high response rate and durable remissions, but the access to this therapy is limited by multiple factors.
Researchers from Kirilys Therapeutics Inc. presented findings from the preclinical evaluation of KRLS-017, a novel reversible cyclin-dependent kinase 7 (CDK7) inhibitor being developed for the treatment of advanced solid tumors.
Researchers from Royal College of Surgeons in Ireland (RCSI) have created a new orthotopic preclinical model of glioblastoma (GBM), designed to recapitulate patient response to standard-of-care and targeted treatments.
RSS
